ERBB2 and gastric cancer: Later, the Trastuzumab for Gastric Cancer (ToGA) clinical trial demonstrated the significant efficacy of trastuzumab in addition to chemotherapy in patients with HER2-positive GC; however, resistance to trastuzumab is a major problem in clinical practice.